VuCOMP, a US-based developer of advanced computer vision systems for the detection of breast cancer, has received US Food and Drug Administration (FDA) approval for its M-Vu computer-aided detection (CAD) for mammography version 3.2.
VuCOMP said the new version of the M-Vu CAD algorithm will offer increased sensitivity, resulting in an improvement in mass detection performance.
The new system is the first mammography CAD product to meet the FDA standard that recommends comprehensive reader studies to prove the effectiveness of CAD systems.
The company continues to offer systematic product updates, fulfilling its commitment to ongoing improvements for its customers.
VuCOMP president Jim Pike said: “We are committed to providing our customers and the industry with the most advanced CAD solution for mammography.
“M-Vu CAD version 3.2 delivers yet another enhancement to our product line, which demonstrates our dedication to the continuous improvement of our offerings.”
Apart from M-Vu CAD, the company secured FDA approval for M-Vu Breast Density in December 2013. The two products were adopted by leading radiologists and are in use in clinics worldwide.
In June 2014, VuCOMP secured approval from the FDA for M-Vu CAD for mammography version 3.1. In order to identify areas of a mammogram that are consistent with breast cancer, the M-Vu CAD system uses advanced computer vision algorithms.
M-Vu CAD is approved for digital mammography systems produced by Carestream, Fuji, GE, Giotto, Hologic, Konica Minolta, Philips, Planmed, and Siemens.